Shots: Providence to receive $100M up front for Providence’s PTX-COVID19-B, mRNA technology & other products, ~$300M upon achievement of milestones, $100M in profit-sharing along with royalties in Greater China & Singapore. Providence is also eligible to receive royalties based on vaccine sales in Everest Territories Everest gains rights to Providence’s PTX-COVID19-B in Greater China, Asia, …
The short answer is that cancer vaccines represent no silver bullet but, in combination with other immunotherapy and drug cocktails, can prove potent.
Too many cold chain suppliers are still monitoring deliveries and storage compliance with paper-based documentation by individuals scanning thermometers every two hours. Such systems fall short of 21st-Century requirements for biologic medicine.